| Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer D Cunningham, S Pyrhönen, RD James, CJA Punt, TF Hickish, R Heikkila, ... The Lancet 352 (9138), 1413-1418, 1998 | 1571 | 1998 |
| Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer P Rougier, E Van Cutsem, E Bajetta, N Niederle, K Possinger, R Labianca, ... The Lancet 352 (9138), 1407-1412, 1998 | 1252 | 1998 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1009 | 2013 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 908 | 2014 |
| Continuous lenalidomide treatment for newly diagnosed multiple myeloma A Palumbo, R Hajek, M Delforge, M Kropff, MT Petrucci, J Catalano, ... New England Journal of Medicine 366 (19), 1759-1769, 2012 | 908 | 2012 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 445 | 2014 |
| A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with … JR Hecht, T Trarbach, E Jaeger, J Hainsworth, R Wolff, K Lloyd, G Bodoky, ... Journal of Clinical Oncology 23 (16_suppl), LBA3-LBA3, 2005 | 264 | 2005 |
| Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a … C Pozzo, C Barone, J Szanto, E Padi, C Peschel, J Bükki, V Gorbunova, ... Annals of Oncology 15 (12), 1773-1781, 2004 | 229 | 2004 |
| Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib PG Richardson, D Siegel, R Baz, SL Kelley, NC Munshi, J Laubach, ... Blood, The Journal of the American Society of Hematology 121 (11), 1961-1967, 2013 | 222 | 2013 |
| Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial YJ Bang, WK Kang, YK Kang, HC Kim, C Jacques, E Zuber, B Daglish, ... Japanese Journal of Clinical Oncology 32 (7), 248-254, 2002 | 190 | 2002 |
| Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma A Palumbo, FM Gay, F Cavallo, F Di Raimondo, A Larocca, I Hardan, ... Journal of Clinical Oncology 33 (30), 3459-3466, 2015 | 179 | 2015 |
| Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study A Bourrier, F Carrat, JF Colombel, AM Bouvier, V Abitbol, P Marteau, ... Alimentary pharmacology & therapeutics 43 (2), 252-261, 2016 | 136 | 2016 |
| Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction E Raymond, V Boige, S Faivre, GJ Sanderink, O Rixe, L Vernillet, ... Journal of clinical oncology 20 (21), 4303-4312, 2002 | 135 | 2002 |
| Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC … C Koehne, E Bajetta, E Lin, E Van Cutsem, J Hecht, J Douillard, M Moore, ... Journal of Clinical Oncology 24 (18_suppl), 3508-3508, 2006 | 111 | 2006 |
| Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours EN Scott, G Meinhardt, C Jacques, D Laurent, AL Thomas Expert opinion on investigational drugs 16 (3), 367-379, 2007 | 109 | 2007 |
| Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial CH Köhne, R Catane, B Klein, M Ducreux, P Thuss-Patience, N Niederle, ... British journal of cancer 89 (6), 997-1001, 2003 | 105 | 2003 |
| High risk of anal and rectal cancer in patients with anal and/or perianal Crohn’s disease L Beaugerie, F Carrat, S Nahon, JD Zeitoun, JM Sabaté, L Peyrin-Biroulet, ... Clinical Gastroenterology and Hepatology 16 (6), 892-899. e2, 2018 | 100 | 2018 |
| Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone MA Dimopoulos, KC Weisel, KW Song, M Delforge, L Karlin, ... haematologica 100 (10), 1327, 2015 | 88 | 2015 |
| A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients≥ 65 years with newly diagnosed multiple myeloma (NDMM … A Palumbo, M Delforge, J Catalano, R Hajek, M Kropff, MT Petrucci, Z Yu, ... Blood 116 (21), 622, 2010 | 88 | 2010 |
| A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma. A Palumbo, MA Dimopoulos, M Delforge, M Kropff, R Foa, Z Yu, L Herbein, ... Blood 114 (22), 613, 2009 | 76 | 2009 |
